Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Dr. Meng and his colleagues found that patients in the aumolertinib arm had a longer progression-free survival than patients randomized to the placebo group. Median PFS by BICR was 30.4 months for ...

Upadacitinib 15 mg and 30 mg maintained treatment efficacy and demonstrated a consistent safety profile over 5 years among patients with RA.

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...